These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 21774822)

  • 41. HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
    Bauersachs J; Störk S; Kung M; Waller C; Fidler F; Hoyer C; Frantz S; Weidemann F; Ertl G; Angermann CE
    Eur J Clin Invest; 2007 Nov; 37(11):852-9. PubMed ID: 17973781
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
    Zhao SP; Yu BL; Peng DQ; Huo Y
    Atherosclerosis; 2014 Apr; 233(2):707-712. PubMed ID: 24603217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
    Han KH; Rha SW; Kang HJ; Bae JW; Choi BJ; Choi SY; Gwon HC; Bae JH; Hong BK; Choi DH; Han KR
    J Clin Lipidol; 2012; 6(4):340-51. PubMed ID: 22836071
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
    Cowell SJ; Newby DE; Prescott RJ; Bloomfield P; Reid J; Northridge DB; Boon NA;
    N Engl J Med; 2005 Jun; 352(23):2389-97. PubMed ID: 15944423
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial.
    Hibi K; Kimura T; Kimura K; Morimoto T; Hiro T; Miyauchi K; Nakagawa Y; Yamagishi M; Ozaki Y; Saito S; Yamaguchi T; Daida H; Matsuzaki M;
    Atherosclerosis; 2011 Dec; 219(2):743-9. PubMed ID: 21899843
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database.
    Jameson K; Zhang Q; Zhao C; Ramey DR; Tershakovec AM; Gutkin SW; Marrett E
    Curr Med Res Opin; 2014 Apr; 30(4):655-65. PubMed ID: 24495126
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study.
    Chitose T; Sugiyama S; Sakamoto K; Shimomura H; Yamashita T; Hokamaki J; Tsunoda R; Shiraishi S; Yamashita Y; Ogawa H
    Atherosclerosis; 2014 Nov; 237(1):251-8. PubMed ID: 25262434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
    Schoenhagen P; Tuzcu EM; Apperson-Hansen C; Wang C; Wolski K; Lin S; Sipahi I; Nicholls SJ; Magyar WA; Loyd A; Churchill T; Crowe T; Nissen SE
    Circulation; 2006 Jun; 113(24):2826-34. PubMed ID: 16769916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation.
    Liu M; Wang F; Wang Y; Jin R
    Cardiovasc Drugs Ther; 2009 Oct; 23(5):369-76. PubMed ID: 19636689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
    Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J;
    JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systemic lupus erythematosus risk factors for coronary artery calcifications.
    Romero-Díaz J; Vargas-Vóracková F; Kimura-Hayama E; Cortázar-Benítez LF; Gijón-Mitre R; Criales S; Cabiedes-Contreras J; Iñiguez-Rodríguez Mdel R; Lara-García EA; Núñez-Alvarez C; Llorente L; Aguilar-Salinas C; Sánchez-Guerrero J
    Rheumatology (Oxford); 2012 Jan; 51(1):110-9. PubMed ID: 22039268
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 54. STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery.
    Neilipovitz DT; Bryson GL; Taljaard M
    Can J Anaesth; 2012 Jun; 59(6):527-37. PubMed ID: 22528165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?
    Vernaglione L; Cristofano C; Muscogiuri P; Chimienti S
    Am J Kidney Dis; 2004 Mar; 43(3):471-8. PubMed ID: 14981605
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled for percutaneous coronary intervention.
    Ishii H; Nishio M; Takahashi H; Aoyama T; Tanaka M; Toriyama T; Tamaki T; Yoshikawa D; Hayashi M; Amano T; Matsubara T; Murohara T
    Clin Ther; 2010 Dec; 32(14):2337-47. PubMed ID: 21353104
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
    Macin SM; Perna ER; Farías EF; Franciosi V; Cialzeta JR; Brizuela M; Medina F; Tajer C; Doval H; Badaracco R
    Am Heart J; 2005 Mar; 149(3):451-7. PubMed ID: 15864233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.
    Budoff MJ; Kessler P; Gao YL; Qunibi W; Moustafa M; Mao SS
    Acad Radiol; 2008 Jan; 15(1):58-61. PubMed ID: 18078907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
    Stalenhoef AF; Ballantyne CM; Sarti C; Murin J; Tonstad S; Rose H; Wilpshaar W
    Eur Heart J; 2005 Dec; 26(24):2664-72. PubMed ID: 16143705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
    Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O;
    Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.